KaloBios Pledges To Do The Right Thing On Drug Pricing
This article was originally published in The Pink Sheet Daily
Executive Summary
In an interview, CEO Cameron Durrant said the time was right for KaloBios to outline its pricing strategy as the company looks to emerge from the Martin Shkreli scandal and bankruptcy.